Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128531) titled 'Clinical Evaluation of Oxaliplatin-Based Doublet Regimens as Adjuvant Therapy for Gastroenteric Neuroendocrine Carcinoma: Efficacy and Safety' on July 22.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
Condition:
Gastrointestinal neuroendocrine tumors
Recruitment Status: Recruiting
Phase: 4
Date of First Enrollment: 2026-04-21
Target Sample Size: XELOX (oxaliplatin combined with capecitabine) :42;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=3290...